Atara Biotherapeutics Inc. [NASDAQ: ATRA] surged by $0.37 during the normal trading session on Wednesday and reaching a high of $4.62 during the day while it closed the day at $4.60. The company report on August 8, 2022 that Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets.
ATA188 Phase 2 EMBOLD Study Interim Analysis Completed with Target Enrollment Achieved; Primary Endpoint Data Read Out Planned for October 2023.
Atara Biotherapeutics Inc. stock has also loss -2.54% of its value over the past 7 days. However, ATRA stock has declined by -1.92% in the 3 months of the year. Over the past six months meanwhile, it has lost -63.95% and lost -70.81% year-on date.
The market cap for ATRA stock reached $462.39 million, with 101.60 million shares outstanding and 93.69 million shares in the current float. Compared to the average trading volume of 2.44M shares, ATRA reached a trading volume of 2410006 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Atara Biotherapeutics Inc. [ATRA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATRA shares is $18.79 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATRA stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Atara Biotherapeutics Inc. shares, keeping their opinion on the stock as Sell, with their previous recommendation back on July 20, 2022. While these analysts kept the previous recommendation, Stifel raised their target price from $16 to $5. The new note on the price target was released on July 13, 2022, representing the official price target for Atara Biotherapeutics Inc. stock. Previously, the target price had yet another raise to $10, while JP Morgan analysts kept a Neutral rating on ATRA stock. On May 10, 2022, analysts decreased their price target for ATRA shares from 15 to 8.
The Average True Range (ATR) for Atara Biotherapeutics Inc. is set at 0.42, with the Price to Sales ratio for ATRA stock in the period of the last 12 months amounting to 6.44. The Price to Book ratio for the last quarter was 1.82, with the Price to Cash per share for the same quarter was set at 3.30.
ATRA stock trade performance evaluation
Atara Biotherapeutics Inc. [ATRA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.54. With this latest performance, ATRA shares gained by 46.03% in over the last four-week period, additionally sinking by -63.95% over the last 6 months – not to mention a drop of -66.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATRA stock in for the last two-week period is set at 50.75, with the RSI for the last a single of trading hit 52.83, and the three-weeks RSI is set at 49.00 for Atara Biotherapeutics Inc. [ATRA]. The present Moving Average for the last 50 days of trading for this stock 5.19, while it was recorded at 4.44 for the last single week of trading, and 10.11 for the last 200 days.
Atara Biotherapeutics Inc. [ATRA]: An insightful look at the core fundamentals
Atara Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.30 and a Current Ratio set at 5.30.
Atara Biotherapeutics Inc. [ATRA]: Insider Ownership positions
There are presently around $460 million, in the hands of institutional investors. The top three institutional holders of ATRA stocks are: JPMORGAN CHASE & CO with ownership of 8,861,252, which is approximately 8.197% of the company’s market cap and around 1.70% of the total institutional ownership; BLACKROCK INC., holding 8,764,706 shares of the stock with an approximate value of $40.32 million in ATRA stocks shares; and BAUPOST GROUP LLC/MA, currently with $37.37 million in ATRA stock with ownership of nearly 0% of the company’s market capitalization.
71 institutional holders increased their position in Atara Biotherapeutics Inc. [NASDAQ:ATRA] by around 7,090,679 shares. Additionally, 72 investors decreased positions by around 4,793,297 shares, while 23 investors held positions by with 88,131,390 shares. The mentioned changes placed institutional holdings at 100,015,366 shares, according to the latest SEC report filing. ATRA stock had 22 new institutional investments in for a total of 1,962,659 shares, while 31 institutional investors sold positions of 866,409 shares during the same period.